Neumora Therapeutics(NASDAQ) NMRA

Neumora creates new medicines for brain and mental health conditions. These drugs help people with depression, Alzheimer's, and schizophrenia. The company tests these treatments to ensure they work safely.

What's in the Pipeline?

• Navacaprant: A once-daily oral pill for major depressive disorder currently in Phase 3 clinical trials, which is the final stage of human testing.
• NMRA-511: An experimental drug designed to treat agitation and distress in patients with Alzheimer's disease.
• Schizophrenia Programs: Includes NMRA-898 and NMRA-NMDA, which target specific brain receptors to manage psychiatric symptoms.
• Neurodegenerative Research: Early-stage programs targeting Parkinson's disease and amyotrophic lateral sclerosis, a condition that affects nerve cells in the brain and spinal cord.
• NMRA-215: A brain-penetrant oral medicine being developed to treat obesity by targeting specific inflammatory pathways.

Strategic Deals and Research Steps

• Acquired BlackThorn Therapeutics in 2020 to gain access to its primary brain research assets and clinical programs.
• Signed license agreements with Amgen in 2021 for compounds targeting proteins linked to neurodegenerative diseases.
• Obtained a worldwide license from Vanderbilt University in 2022 to develop treatments for schizophrenia and other disorders.
• Received research funding from The Michael J. Fox Foundation in late 2024 and 2025 to support Parkinson's disease research.

How Neumora Tries to Win

Neumora uses a precision neuroscience approach to match brain treatments with specific patient groups. This strategy uses data and biology to improve the success rate of complex drug development compared to traditional methods.

The Financial Scoreboard

• Operating loss was $52.9 million in Q1 2026, which improved 25.5% from the same period in 2025.
• Net loss reached $53.5 million in Q1 2026, an improvement of 21.4% from the prior year.
• Cash and cash equivalents totaled $147.1 million as of March 31, 2026.
• Accumulated deficit, representing the company's total losses since it started, hit $1.2 billion by March 31, 2026.

Company Evolution

Neumora has moved from early research to late-stage clinical testing of brain therapies. Its focus on data-driven precision medicine and strategic licenses with larger firms defines its current path.